{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:11:40Z","timestamp":1770747100586,"version":"3.49.0"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To describe our managing strategy for COVID-19 emergency, to evaluate the adherence to intravitreal treatment (AtT) rate during the outbreak in a referral hospital in Milan, and to correlate it with patients' clinical features.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The AtT rate of patients with scheduled intravitreal injections during the COVID-19 outbreak from February 23, 2020 to March 31, 2020 was compared with the previous trimester and with March 2019. The impact of age, sex, visual function, and diagnosis on the AtT rate during unlocked\/locked weeks (from March 8th) was evaluated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 650 consecutive patients with scheduled intravitreal injections, the AtT rate during the COVID-19 outbreak was 0.37. This was significantly lower compared with AtT registered in the previous trimester (0.92) and in the same weeks in 2019 (0.90) (both <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Patients adherent to treatment were significantly younger (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) and had a lower best-corrected visual acuity in the fellow eye (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.046). During the lockdown weeks, the AtT rate was significantly lower than in the two unlocked weeks (0.19 vs. 0.73, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). In addition, the AtT rate in patients classified as \u201cemergent\u201d during the lockdown weeks was 0.60.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>These preliminary results can help the retina specialist community to foresee this unique scenario and to develop successful management strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000002941","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T01:05:49Z","timestamp":1597367149000},"page":"701-705","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":31,"title":["IMPACT OF CORONAVIRUS DISEASE PANDEMIC ON INTRAVITREAL INJECTIONS TREATMENT FOR MACULAR DISEASES"],"prefix":"10.1097","volume":"41","author":[{"given":"Francesco","family":"Viola","sequence":"first","affiliation":[{"name":"Ophthalmological Unit, Department of Clinical Sciences and Community Health, Ca' Granda Foundation\u2014Maggiore Policlinico Hospital, University of Milan, Milan, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Milella","sequence":"additional","affiliation":[{"name":"Ophthalmological Unit, Department of Clinical Sciences and Community Health, Ca' Granda Foundation\u2014Maggiore Policlinico Hospital, University of Milan, Milan, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Pozzo Giuffrida","sequence":"additional","affiliation":[{"name":"Ophthalmological Unit, Department of Clinical Sciences and Community Health, Ca' Granda Foundation\u2014Maggiore Policlinico Hospital, University of Milan, Milan, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"Ganci","sequence":"additional","affiliation":[{"name":"Ophthalmological Unit, Department of Clinical Sciences and Community Health, Ca' Granda Foundation\u2014Maggiore Policlinico Hospital, University of Milan, Milan, Italy;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Invernizzi","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Clinical Science \u201cLuigi Sacco,\u201d Eye Clinic, Luigi Sacco Hospital, University of Milan, Milan, Italy; and"},{"name":"Save Sight Institute, University of Sydney, Sydney, New South Wales, Australia."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"New Engl J Med"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jfo.2020.04.019","article-title":"Quelle conduite \u00e0 tenir adopter vis \u00e0 vis des injections intravitr\u00e9ennes (IVT) dans cette p\u00e9riode d'\u00e9pid\u00e9mie au covid-19\u2014SARS-CoV-2? [in French].","volume":"43","author":"Kodjikian","year":"2020","journal-title":"J Fr Ophtalmol"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00417-020-04703-x","article-title":"Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic","volume":"258","author":"Korobelnik","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"The Lancet"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s12325-020-01236-x","article-title":"Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial","volume":"37","author":"Ohji","year":"2020","journal-title":"Adv Ther"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.preteyeres.2017.12.002","article-title":"Real-world outcomes in patients with age-related macular degeneration treated with intravitreal vascular endothelial growth factor inhibitors","volume":"65","author":"Mehta","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00417-020-04697-6","article-title":"Guidance for patients with nAMD and their families during the COVID-19 pandemic","volume":"258","author":"Korobelnik","year":"2020","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:05:59Z","timestamp":1749319559000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002941"}},"subtitle":["Report From a Referral Hospital in Milan"],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002941","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}